dementia for fracp1 final2
TRANSCRIPT
![Page 1: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/1.jpg)
Dementia for the FRACP Part 1Rohan Gunathilake MD
![Page 2: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/2.jpg)
What is Dementia?
1. Acquired neurocognitive decline 2. Across one or more domains3. Interferes with independence4. Not due to delirium or other
psychiatric disorder
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 2013
![Page 3: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/3.jpg)
What is new in DSM-5?
• Major Neurocognitive Disorder (dementia is gone - not really!)
• Domains: Learning and memory, complex attention, language, perceptual-motor, executive function, and social cognition
• Memory loss is not an essential criteria• Psychometric definition for major vs. minor
NCD
![Page 4: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/4.jpg)
Major vs. Minor Neurocognitive Disorder
Note: Should not be rigid – Major and minor exist in a continuum
![Page 5: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/5.jpg)
![Page 6: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/6.jpg)
Risk factors for dementia
Non-modifiable• Advancing age• Female gender• Educational achievement• Ethnicity: African American• Family history (x2.5)• Specific genetic mutations• MCI• Head injury
ModifiableIncreased Risk• Hypertension• Diabetes• Smoking• Hypercholesterolemia• Hyperhomocysteinemia
Decreased Risk• Physical exercise• Diet
![Page 7: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/7.jpg)
Prevalence of dementia nearly doubles every 5 years after the age of 60
Ferri et al, Lancet 2005
![Page 8: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/8.jpg)
Risk factors for dementia
Non-modifiable• Advancing age• Female gender• Educational achievement• Ethnicity: African American• Family history (x2.5)• Specific genetic mutations• MCI• Head injury
ModifiableIncreased Risk• Hypertension• Diabetes• Smoking• Hypercholesterolemia• Hyperhomocysteinemia
Decreased Risk• Physical exercise• Diet
![Page 9: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/9.jpg)
Genetic factors in Alzheimer Dementia
Loy et al, Lancet 2014
![Page 10: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/10.jpg)
Mendelian forms of AD
• Fortunately rare – only 500 families with AD• Autosomal dominant with high penetrance• Life time risk of developing dementia >95%• Multigenerational • Younger onset• May have myoclonus at early stages• 3 causative genes: APP (chromosome 21),
PSEN 1 (Chro 14) and PSEN 2 (Chro 1)
![Page 11: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/11.jpg)
Loy et al, Lancet 2014
![Page 12: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/12.jpg)
Mendelian forms of AD
• PSEN 1 – accounts for 60% Mendelian AD families
• APP– Sequence mutation 15%– Duplication 8%
• PSEN 2 – rare**86% families with younger onset (<60 years) AD and >3 generations affected are +ve consider genetic testing
Loy et al, Lancet 2014
![Page 13: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/13.jpg)
Genetically complex AD
• Polygenic (genetically complex) variations – each increase risk by small amount only (+ environment)
• Late onset• Unlikely to pass all genetic variations to the
offspring• Can skip generations• Genetic testing have poor predictive power
Loy et al, Lancet 2014
![Page 14: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/14.jpg)
Genetically complex AD
• Among known genetic variations, apo E and TREM 2 are best characterized
• Normal genotype = E3/E3 (61%)• OR for AD: E2/E2 = 1.5
E3/E4 (24%) = 3E4/E4 (2%) = 8
![Page 15: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/15.jpg)
Genetically complex AD
Nature Reviews Neuroscience 10, 333-344 (2009)
![Page 16: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/16.jpg)
Genetically complex AD
• 75% with once copy of E4 do not develop AD• 50% with AD do not have E4 variation• Genetic testing has poor predictive value and
is not recommended
![Page 17: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/17.jpg)
Neuropathology of AD
Varon et al, Dement Geriatr Cogn Disord 2011
![Page 18: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/18.jpg)
Pathogenesis AD
1. Amyloid (Senile) plaques – extracellular- protein fragments snipped from APP
2. Neurofibrillary tangles – intracellular-chemically altered tau tangled with other threads
![Page 19: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/19.jpg)
Aβ42
Aβ40
Oligomers&Intermediateforms
Amyloid plaques
inflammation
NEJM 2010; 362:329-44
![Page 20: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/20.jpg)
![Page 21: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/21.jpg)
NEJM 2010; 362:329-44
![Page 22: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/22.jpg)
![Page 23: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/23.jpg)
Synaptic loss
![Page 24: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/24.jpg)
Giacobini, Nat. Rev. Neurol. doi:10.1038/nrneurol.2013.223
Amyloid hypothesis in AD- summary
Apo E4
![Page 25: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/25.jpg)
Clinical features of AD
NEUROLOGY 2005;65(Suppl 3):S10–S17
![Page 26: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/26.jpg)
Clinical features of AD
![Page 27: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/27.jpg)
Nature Reviews Drug Discovery 2007; 6, 295-303
![Page 28: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/28.jpg)
Lancet Neurol. 2013;12(2)-207-16
![Page 29: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/29.jpg)
Amyloid imaging with 11C-PIB PET
Transaxial and sagittal planes of 11C-PIB PET scans in a normal control (NC), a 11C-PIB-positive NC (NC+), 11C-PIB-negative MCI subject (MCI−), a 11C-PIB-positive MCI subject (MCI+), a highly 11C-PIB-positive MCI subject (MCI++), and a 11C-PIB-positive AD patient (AD) J. Med. Chem. 2007; 46, 2740–2754
![Page 30: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/30.jpg)
Mean CSF Aβ42 and total tau levels in autopsied proven cases
CSF Aβ42 CSF total tau
Schoonenboom et al, Neurology 62, 1580–1584
![Page 31: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/31.jpg)
Treatment of Alzheimer Disease
Non-pharmacological• Carer support• Education• Socialisation• Cognitive engagement• Nutrition• Exercise• Smoking and ETOH• Diving and home safety• Advanced Care planning
Pharmacological• Cholinesterase Inhibitors• Memantine
![Page 32: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/32.jpg)
![Page 33: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/33.jpg)
Cholinesterase inhibitors mechanism of action
Eur Heart J. 2013;34(33):2580-2581
![Page 34: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/34.jpg)
Memantine mechanism of action
CNS Drugs 2003: 17 (9)
![Page 35: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/35.jpg)
![Page 36: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/36.jpg)
Aricept product monograph, Pfizer
![Page 37: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/37.jpg)
Rivastigmine patch in mild to moderate AD
Int J Geriatr Psychiatry. 2007 May;22(5):456-67
![Page 38: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/38.jpg)
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg B et al. N Engl J Med 2003;348:1333-1341.
![Page 39: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/39.jpg)
Therapeutic targets in AD
BASE 1 inhibitors
BapineuzumabSolanezumab
![Page 40: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/40.jpg)
Behavioural and psychological symptoms of dementia (BPSD)
![Page 41: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/41.jpg)
Management of BPSD
Non-pharmacological• Behavioural intervention• Music therapy• Pet therapy• Aromatherapy• Bright light therapy
Pharmacological• Choline esterase Inhibitors• Memantine• Atypical antipsychotics• Antidepressants:
citalopram, SSRI• Antiepileptics
![Page 42: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/42.jpg)
Past FRACP1 Questions
![Page 43: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/43.jpg)
An 87-year-old woman with dementia was found wandering late at night. When she was returned to her home, it was found to be infested, unlocked and the gas stove was on. Her MMSE was 13/30. After hospitalisation, it is apparent that she requires residential care. However, she demands to return home. Her nearest relative is a second cousin living in another city but has not been in contact with her for several years. Her neighbour has been informally acting as a caregiver and providing limited supervision. Who should make the decision regarding institutionalisation in residential care?A. PatientB. Relative (second cousin)C. Carer (neighbour)D. Statutory guardianE. Medical practitioner
![Page 44: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/44.jpg)
An 80 year-old lady has end-stage dementia and lives in a HLC nursing home. She is doubly incontinent, bed bound and doesn’t recognize family members. She has developed a new neurological dysphagia. She coughs lots when given thin fluids and aspirates. She spits out thickened fluids. She has been admitted to hospital twice with aspiration pneumonia. She has been made nil by mouth while awaiting assessment but appears to be distressed by not being allowed to eat and drink. What is the appropriate treatment?A. PEG feedingB. Nasogastric feedingC. Keep her nil by mouth and give subcutaneous fluidsD. Allow her to have any food or drink that she wantsE. Thickened fluids only
![Page 45: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/45.jpg)
A 75-year-old woman presents with a twelve-month history of deteriorating behaviour and memory and increasing social withdrawal. She has been tearful and emotional with poor quality sleep. A diagnosis of depression has been made by her general practitioner, and she has been commenced on Sertraline 50mg / day with a limited response over the last eight weeks. Neurological examination reveals normal tone and no pyramidal findings. She scores 21/30 on a MMSE. TSH, full blood count, urea and electrolytes, calcium and liver function tests are normal. Cranial CT Scan shows age related involutional change. Her EEG demonstrates diffuse symmetrical slowing over both frontotemporal head regions with an excess of delta activity.The most likely diagnosis is:A. undertreated Major depressionB. diffuse Lewy body disease with associated depressionC. Alzheimers type dementia with associated depressionD. Creutzfeldt Jakob disease with associated depressionE. depression with hysterical conversion disorder
![Page 46: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/46.jpg)
![Page 47: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/47.jpg)
• The most common reason for reduced oral intake in people with end stage dementia is:A. impaired swallowingB. deliberate self harmC. physical inactivityD. increased metabolic rateE. dental disease
![Page 48: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/48.jpg)
For a patient aged above 75 years old, what is the most likely risk factor for late onset dementia?A. Homozygous ApoE defectB. HypertensionC. Atrophy on CT brainD. Advancing ageE. Mild cognitive impairment
![Page 49: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/49.jpg)
The clinical diagnosis of Alzheimer's type dementia requires:A. apraxiaB. agnosiaC. impaired consciousnessD. impaired functionE. inattention
![Page 50: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/50.jpg)
A 79 year old man is brought in by his daughter after she notes he has mild confusion. His MMSE is 25/30. He is unable to draw intersecting pentagons. When asked to draw a clock face, the numbers are crowded to the right side. He is unable to dress himself, but has no weakness.What is the most likely diagnosis?A. Progression of dementiaB. Delirium with sedative useC. Right lacunar strokeD. Right posterior cerebral artery branch strokeE. Right middle cerebral artery branch stroke
![Page 51: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/51.jpg)
An 80 year old lady is found wandering on the street. There is no useful history from the patient. On examination, she is drowsy and is disoriented to time and place. Her temperature is 37.9 degrees Celsius, BP is 125/80 mmHg and pulse rate is 100/minute. She appears to be having auditory and visual hallucinations. Which of the following features will indicate likely delirium rather than dementia?A. Disorientation to time and placeB. DrowsinessC. Fever of 37.9 degrees CelsiusD. HallucinationsE. Tachycardia
![Page 52: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/52.jpg)
70 year old gentlemen presented to OPD for falls investigation. Physical examination reveals intention tremor and mild ataxic gait. Mild cognitive impairment also noted. The patient’s daughter’s son had recently been diagnosed with intellectual impairment. What is the most likely underlying genetic defect?A. Freidrich’s AtaxiaB. Fragile X syndromeC. Huntington’s diseaseD. Spinocerebellar ataxia type 1
![Page 53: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/53.jpg)
An 80 year old man with dementia is still living at home with his wife as his principal carer. He was recently commenced on risperidone for behavioural and aggression issues. He has been refusing to take the risperidone and his wife has been crushing it and putting it in his food. What principle ofmedical ethics does this most contravene?A. AutonomyB. BeneficenceC. Distributive justiceD. Non maleficence‐E. Competency
![Page 54: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/54.jpg)
Cholinesterase inhibitors are widely used to improve cognitive function in Alzheimer's disease. Which of the following urinary symptoms would be the most likely type A (dose-dependent) adverse drug reaction?A. Increased urinary frequencyB. Reduced urine outputC. Increased urine outputD. Urinary retentionE. Stress incontinence
![Page 55: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/55.jpg)
An elderly patient complains of subjective memory loss and poor performance. In which aspect of the MMSE will a deficit suggest future development of dementia?A. RegistrationB. Recall and memoryC. Figure copying eg. Intersecting pentagonsD. Attention and calculationE. Language
![Page 56: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/56.jpg)
An 82-year-old male has had Parkinson's disease for ten years. His current medications include levodopa/carbidopa and pergolide. For the last 18 months he has been in high level care (nursing home) because of his immobility but can still walk five-ten metres with a forearm support frame. His MMSE is 26/30. For the last three-six months he has had increasing problems with hallucinations of people coming into his room and has repeatedly accused his family members of stealing money from his bank account. The most appropriate first step in the management of his hallucinations and paranoia is:A. commence risperidoneB. commence clozapineC. cease pergolideD. reduce dose of levodopa/carbidopaE. commence trimethoprim
![Page 57: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/57.jpg)
In a patient with extrapyramidal symptoms, which of the following is more suggestive of Lewy bodydisease than Parkinson’s disease?A. Rest tremorB. RigidityC. Visual hallucinationsD. Response to dopaminergic agonistsE. Bradykinesia
![Page 58: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/58.jpg)
PDD and LBD
• PD and DLB not 2 separate entities but represent a spectrum of same pathological process; difference because of parts of the brain affected• Neo cortical and Limbic deposition of:
1. Lewy Bodies: Eosinophilic inclusions found in the nerve cells made up of Ubiquitin and aggregations of Alpha Synculein
2. Lewy Neurites : Thread like inclusions within neurites
• LBD - Early involvement of Amygdala – cognitive changes, and temporal lobe - hallucinations
![Page 59: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/59.jpg)
Parkinson Disease Dementia
• 1 year rule: PDD = onset of dementia > 1 year after diagnosis of PD
• By 15 years >80% with PD have dementia• Prominent impairment of executive function• Bradyphrenia• Retrieval > encoding difficulty • Visuospatial dysfunction• PD motor features (in AD it’s axial)
![Page 60: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/60.jpg)
Lewy Body Dementia
Core Features:1. Fluctuating cognition2. Visual hallucinations3. Spontaneous parkinsonism
Suggestive features:4. REM sleep behaviour disorder5. Neuroleptic sensitivity6. Low dopamine transporter uptake (PET/ SPECT)
![Page 61: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/61.jpg)
Management of LBD/ PDD
• Cholinergic deficit in DLB• Rivastigmine improved cognition and behaviour in
DLB cf to placebo in a 20-week study (McKeith et al, 2000)
• Rivastigmine –treated patients with PDD had better cognitive and global scores than placebo at 24 weeks (Emre et al, 2004)
• Agitated psychotic and behavior – clozapine or quetiapine
• REM Sleep behavior disorder – clonazepam, CEIs
![Page 62: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/62.jpg)
Vascular dementia
1. Dementia (decline from previous higher level of functioning)
2. Cerebrovascular disease:– focal neurologic signs consistent with previous stroke
(even with negative stroke history)– evidence of relevant cerebrovascular disease by CT or
MRI scan3. A clear temporal relationship– Onset< 3 months/ abrupt cognitive decline/stepwise
progressionNational Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences [NINDS-AIREN], 1993
![Page 63: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/63.jpg)
clinical subtypes of VaD
1. Multi-infarct dementia – large complete cortical or subcortical infarcts
2. Strategic infarct dementia – single infarct in functionally critical areas e.g. angular gyrus, thalamus, PCA
3. Subcortical ischemic VaD– Lacunar states– Binswagner syndrome– CADASIL– Cerebral amyloid angiopathy
![Page 64: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/64.jpg)
Clinical presentation of VaD
Cognitive• Slow processing• Executive dysfunction• Memory impairment
(retrieval deficit)• Depression • Apathy
Motor• Focal cortical impairments• Pseudobulbar palsy• Extrapyramidal signs
![Page 65: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/65.jpg)
Frontotemporal dementias
• Common cause of presenile (<60 yr) dementia• Genetic advances and pathology suggest these
are multiple and independent illnesses• Pathology: Tau or TDP 43 inclusions
(tauopathy)• Cholinergic pathways relatively spared• Overlap with Amyotrophic Lateral Sclerosis,
![Page 66: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/66.jpg)
Frontotemporal dementia- behavioural variant
• Disinhibition• Apathy• Lack of empathy• Loss of emotional reactivity• Lack of respect to personal space• Rude comments about others• Perseveration• Compulsive behaviors• Hyperorality and hypersexuality
![Page 67: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/67.jpg)
Autoimmune encephalopathies
J Neuropsychiatry Clin Neurosci. 2011;23(1):90-97.
![Page 68: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/68.jpg)
Steroid responsive encephalopathy with autoimmune thyroiditis (SREAT)
• Relapsing and remitting cognitive and behavioral changes
• Tremor, transient aphasia, myoclonus, seizures, gait ataxia
• No other detectable cause; MRI normal in 70%• Usually euthyroid • Abnormal elevation of anti-TPO +/- anti-TG
Elevated CSF protein (75%), cells (25%) and anti-TPO
![Page 69: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/69.jpg)
CJD
1. Sporodic 80-90%– Peak age 55-75 years– Mean survival 7 months
2. Genetic 10%– Autosomal dominant– Family history
3. Iatrogenic– Corneal and dural grafts, GH
![Page 70: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/70.jpg)
![Page 71: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/71.jpg)
Variant CJD is different from CJD
![Page 72: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/72.jpg)
MRI in CJD
CJD – cortical ribbon sign &Hockey stick sign (arrows)
vCJD –Pulvinar sign
![Page 73: Dementia for fracp1 final2](https://reader035.vdocuments.net/reader035/viewer/2022070317/556e40ead8b42a16278b4db2/html5/thumbnails/73.jpg)